Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 479.57M +40.8% |
| Revenue (ttm) | 6.38M |
| Net Income | 201.62M |
| EPS | 4.78 |
| Shares Out | n/a |
| PE Ratio | 2.38 |
| Forward PE | n/a |
| Dividend | 0.79 (6.75%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 9,251 |
| Average Volume | 6,572 |
| Open | 1,179.00 |
| Previous Close | 1,179.00 |
| Day's Range | 1,179.00 - 1,237.00 |
| 52-Week Range | 680.00 - 1,247.00 |
| Beta | 1.26 |
| RSI | 56.83 |
| Earnings Date | Apr 2, 2026 |
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. [Read more]
News
Lifeward closes strategic partnership agreement with Oramed
Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a dive...
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Or...
Oramed and Lifeward sign strategic transaction
Oramed (ORMP) and Lifeward (LFWD) signed binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of...
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intend...
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while reta...
Oramed receives $18M payment from Scilex Holdings
Oramed (ORMP) Pharmaceuticals announced it has received an $18M payment from Scilex Holdings, representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed’s cur...
Oramed declares cash dividend payment of 25c per share
Oramed’s (ORMP) Board of Directors has approved a cash dividend payment of 25c per share to reward shareholders. The dividend will have an ex-dividend date of January 16, with disbursement
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed ...
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) ...
Oramed declares dividend distribution of common stock purchase rights
Oramed (ORMP) has unanimously adopted a Rights Agreement dated November 17 by and between the company and its rights agent, and declared a dividend of one common stock purchase right
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 20...
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partners...
Scilex completes first tranche of Oramed warrant repurchase
Scilex Holding Company (SCLX) repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share from Oramed Pharmaceuticals (ORMP) for $13,000,000. A...
Alpha Tau enters strategic marketing alliance with Oramed
Alpha Tau Medical (DRTS) closed a registered direct offering whereby an affiliate of Oramed Pharmaceuticals (ORMP) purchased 14,110,121 of Alpha Tau’s ordinary shares, no par value, at a purchase pric...
Alpha Tau enters strategic marketing alliance with Oramed
Alpha Tau Medical (DRTS) closed a registered direct offering whereby an affiliate of Oramed Pharmaceuticals (ORMP) purchased 14,110,121 of Alpha Tau’s ordinary shares, no par value, at a purchase pric...
Oramed announces $36.9M investment and collaboration with Alpha Tau
Oramed (ORMP) has closed a strategic investment in Alpha Tau (DRTS). Through a registered direct offering, an affiliate of Oramed purchased approximately 14.1 million Alpha Tau’s ordinary shares, at a
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials a...
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of O...
Oramed enters JV for insulin development and commercialization
Oramed (ORMP) has entered into definitive agreements to spin off its Protein Oral Delivery – POD – technology into a newly formed joint venture, OraTech Pharmaceuticals, with Hefei Tianhui. This
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a dir...
Scilex announces early installment payment on senior secured promissory note
Scilex (SCLX) Holding Company has voluntarily made an early installment payment in the aggregate amount of $13.2 million under its senior secured promissory note issued to Oramed (ORMP) Pharmaceutical...
Oramed announces restructuring of Scilex debt
Oramed Pharmaceuticals (ORMP) announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (SCLX). Ora...
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery pla...
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (...